Research Center on Aging
Sherbrooke, Quebec, J1H 4C4, Canada
NCT Number: NCT06022094
The present study will assess the effects on glucose, ketones and other blood biomarkers fuels, cognition, quality of life, physical activity and well-being of a reduced carbohydrate menu (R-CHO) for 2 months in a population living in a residence for the elderly. This intervention study, identified as the SAGE project (phase 2), follows on from the Ketohome project (phase 1) assessing the feasibility of such a project.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
Sherbrooke, Quebec, J1H 4C4, Canada
Finding an effective therapeutic strategy for Alzheimer's disease (AD) is a societal priority, but it also remains a major challenge. With one exception in 2021, no new pharmaceutical treatment for AD has been approved for over 20 years. However, several clinical trials demonstrate the potential of ketogenic interventions to restore brain energy and improve cognition in people with mild cognitive impairment and AD. Recently, the largest and longest clinical trial of its kind shows that compensating for energy deficit in the brain during aging improves brain metabolic and cognitive functioning in people with early AD and could potentially delay AD.
One of the main types of ketogenic intervention is the highly reduced carbohydrate (5-10% of daily energy value compared to a normal value of 50-65%) and very high fat ketogenic diet. Despite the now well-established safety of the ketogenic diet and its therapeutic value in the treatment of epilepsy and type 2 diabetes, the latter remains difficult to implement in because of the compliance challenge. A reduced glycemic load diet where intake of refined carbohydrates and added sugar is restricted is found to be much less restrictive than a ketogenic diet. Phase 1 of this project showed that decreased carbohydrate (sugar) intake may improve long-term glycemic control and compliance compared to more severe carbohydrate restriction. Having better blood glucose control may also be important in decreasing the risk of AD possibly by improving the metabolic profile and/or by promoting the production and use of ketones. However, its effectiveness in helping cognition in the elderly is still unknown and any changes in dietary habits can be addressed with some resistance.
The objective of this project is therefore to answer the following question: does a reduction in carbohydrates of 30 to 50% for 2 months reduce the risk of AD by improving the metabolic profile in people living in a senior residence?
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will eat a reduced carb menu for 2 months
Other names: R-CHO
Time frame: 2 months
Blood glucose will be monitored continuously with a real-time continuous glucose monitor (CGM) for two 10-days periods; before/after intervention in people in a senior residence.
Time frame: 2 months
Blood ketones will be measured before/after the intervention in people in a senior residence via blood sampling.
Time frame: 2 months
Blood insulin will be measured before/after the intervention in people in a senior residence via blood sampling.
Time frame: 2 months
Blood triglycerides levels will be measured before/after the intervention in people in a senior residence via blood sampling.
Time frame: 2 months
Blood cholesterol levels will be measured before/after the intervention in people in a senior residence via blood sampling.
Time frame: 2 months
Blood glycated hemoglobin levels will be measured before/after the intervention in people in a senior residence via blood sampling.
Université de Sherbrooke
Other
Effect of a Two-month Carbohydrate-restricted Diet on Energy Metabolism in a Seniors' Residence: The SAGE Study
Acronym: SAGE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04149457
Healthy Aging
Montreal, Quebec, Canada
View Trial DetailsNCT04522791
Cognition Disorders, Cognitive Dysfunction
Rochester, New York, United States
View Trial DetailsNCT04848038
Healthy Aging
Fairway, Kansas, United States
View Trial DetailsNCT07623122
Cognition Disorders, Cognitive Decline
Pamplona, Navarre, Spain
View Trial Details